Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 88-95

  Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLAVONOID; HYPERFORIN; HYPERICIN;

ARTICLE; DEPRESSION; DRUG METABOLISM; ENZYME INHIBITION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERICUM PERFORATUM; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; CHLOROGENIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYPERICUM; PERYLENE; PHLOROGLUCINOL; PLANT EXTRACTS; PLANTS, MEDICINAL; QUERCETIN; TERPENES;

EID: 0033917295     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bailey DG, Malcolm J, Arnold O and Spence JD (1998) Grapefruit juice drug interactions. Br J Clin Pharmacol 46:101-110.
2. Berghofer R and Holzl J (1987) Biflavonoids in Hypericum perforatum, part 1. Isolation of I3,II8-biapigenin. Planta Med 216-217.
3. Biber A, Fischer H, Romer A and Chatterjee SS (1998) Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31S:36-43.
4. Brolis M, Gabetta B, Fuzzati N, Pace R, Panzeri F and Peterlongo F (1998) Identification by high-performance liquid chromatography-diode array-mass spectrometry and quantification by high performance liquid chromatography-UV absorbance detection of active constituents of Hypericum perforatum. J Chromatogr A 825:9-16.
5. Chan KK and Pang KS (1982) Synthesis of singly deuterium-, tritium-, and carbon-14- and doubly labeled acetaminophen, phenacetin, and p-acetanisidine. J Label Compd Radiopharm 19:321-329.
6. Christopherson PA, Mankowski DC, Tweedie DJ and Lawton MP (1995) Expression of human cytochromes P450 in insect cells. ISSX Proc 8:358.
7. deGroot MJ, Ackland MJ, Horne VA, Alex AA and Jones BC (1999) A novel approach to predicting P450 mediated drug metabolism: CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:4062-4070.
8. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD and Watkins P (1999) 6′,7′-Djbydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237-244.
9. Erdelmeier CAJ (1998) Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 31S:2-6.
10. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed. (Ortiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
11. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513-1518.
12. Johne A. Brockmoller J, Bauer S, Maurer A, Langheinrich M and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
13. Josey ES and Tackett RL (1999) St. John's wort: A new alternative for depression. Int J Clin Pharmacol Ther 37:111-119.
14. Laakmann G, Schule C, Baghai T and Kieser M (1998) St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31S:54-59.
15. 3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369-1375.
16. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
17. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z and Risch SC (2000) Effect of St. John's wort (Hypericum perforatum} on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66:PL133-PL139.
18. Nahrstedt A and Butterweck V (1997) Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30S:129-134.
19. Orth HCJ, Hauer H, Erdelmeier CAJ and Schmidt PC (1999b) Orthoforin: The main degradation product of hyperforin from Hypericum perforatum L. Pharmazie 54: 76-77.
20. Orth HCJ, Rentel C and Schmidt PC (1999a) Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J Pharm Pharmacol 51:193-200.
21. +1. J Pharmacol Exp Ther 290:1363-1368.
22. Strobl GR, vonKreudener S, Stockigt J, Guengerich FP and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modelling and inhibition studies. J Med Chem 36:1136-1145.
23. Zhai S, Dai R, Friedman FK and Vestal RE (1998) Comparative inhibition of human cytochromes P4501A1 and 1A2 by flavonoids. Drug Metab Dispos 26:989-992.